Favipiravir Effects on the Control of Clinical Symptoms of Hospitalized COVID-19 Cases: An Experience with Iranian Formulated Dosage Form
Tabarsi et al.,
Favipiravir Effects on the Control of Clinical Symptoms of Hospitalized COVID-19 Cases: An Experience with..,
Iranian Journal of Pharmaceutical Research, doi:10.22037/ijpr.2021.115510.15401
Small 62 patient late stage RCT in Iran comparing favipiravir and lopinavir/ritonavir, showing significant improvement in fever, cough, and dyspnea with favipiravir on day 5. There was no significant difference in mortality, ICU admission, or chest CT improvement. IRCT20151227025726N14.
risk of death, 29.7% lower, RR 0.70, p = 0.70, treatment 3 of 32 (9.4%), control 4 of 30 (13.3%), NNT 25.
|
risk of ICU admission, 41.4% lower, RR 0.59, p = 0.36, treatment 5 of 32 (15.6%), control 8 of 30 (26.7%), NNT 9.1.
|
risk of <50% improvement in chest CT, 6.2% lower, RR 0.94, p = 0.76, treatment 24 of 32 (75.0%), control 24 of 30 (80.0%), NNT 20.
|
hospitalization time, 25.0% lower, relative time 0.75, p = 0.03, treatment 32, control 30.
|
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
|
Tabarsi et al., 30 Sep 2021, Randomized Controlled Trial, Iran, peer-reviewed, 27 authors, study period 4 April, 2020 - 7 May, 2020, average treatment delay 7.0 days, this trial compares with another treatment - results may be better when compared to placebo.
Abstract: Iranian Journal of Pharmaceutical Research (2021), 20 (4): 1-8
DOI: 10.22037/ijpr.2021.115510.15401
Received: May 2021
Accepted: September 2021
Original Article
Favipiravir Effects on the Control of Clinical Symptoms of
Hospitalized COVID-19 Cases: An Experience with Iranian
Formulated Dosage Form
Payam Tabarsia , Hossein Vahidib, Ali Saffaeic, Seyed Mohammad Reza Hashemiand,
Hamidreza Jammatid, Bahram Daraeie, Arash Mahboubif, Farzad Kobarfardg, Majid
Marjania, Afshin Moniria, Zahra Abtahiana, Atefeh Abedinid, Alireza Eslaminejadd, Jalal
Heshmatniad, Maryam Sadat Mirenayatd, Atefeh Fakhariand, Sharareh Seifid, Mohsen
Sadeghid, Alireza Dastanh, Sara Haselid, Seyed Alireza Nadjii, Raha Eskandarid, Sahar
Yousefiand, Mohammad Varahramd, Alireza Zalij, Ali Akbar Velayatik and Farzaneh
Dastand, l*
Clinical Tuberculosis and Epidemiology Research Center, National Research Institute
of Tuberculosis and Lung Diseases (NRITLD), Masih Daneshvari Hospital, Shahid Beheshti
University of Medical Sciences, Tehran, Iran. bDepartment of Pharmaceutical Biotechnology,
School of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran. cStudent
Research Committee, Department of Clinical Pharmacy, School of Pharmacy, Shahid Beheshti
University of Medical Sciences, Tehran, Iran. dChronic Respiratory Diseases Research Center
(CRDRC), National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid
Beheshti University of Medical Sciences, Tehran, Iran. eDepartment of Toxico/Pharmacology,
School of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
f
Department of Pharmaceutics and Nanotechnology, School of Pharmacy, Shahid Beheshti
University of Medical Sciences, Tehran, Iran. gDepartment of Medicinal Chemistry, School
of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran. hErnest and
Julio Gallo Management Program, School of Engineering, University of California, Merced,
CA, United States. iVirology Research Center, National Research Institute of Tuberculosis
and Lung Diseases (NRITLD), Masih Daneshvari Hospital, Shahid Beheshti University of
Medical Sciences, Tehran, Iran. jFunctional Neurosurgery Research Center, Shohada Tajrish
Comprehensive Neurosurgical Center of Excellence, Shahid Beheshti University of Medical
Sciences, Tehran, Iran. kTracheal Diseases Research Center, National Research Institute of
Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Sciences,
Tehran, Iran. lDepartment of Clinical Pharmacy, School of Pharmacy, Shahid Beheshti
University of Medical Sciences, Tehran, Iran.
a
* Corresponding author:
E-mail: fzh.dastan@gmail.com
Tabarsi P et al. / IJPR (2021), 20 (4): 1-8
Abstract
Coronavirus disease -19 (COVID-19) pandemic, caused by SARS-CoV-2, has gradually
spread worldwide, becoming a major public health event. This situation requires designing a
novel antiviral agent against the SARS-CoV-2; however, this is time-consuming and the use of
repurposed medicines may be promising. One such medicine is favipiravir, primarily introduced
as an anti-influenza agent in east world. The aim of this study was to evaluate the efficacy and
safety of favipiravir in comparison with lopinavir-ritonavir in SARS-CoV-2 infection. In this
randomized clinical trial, 62 patients were recruited. These patients had bilateral pulmonary
infiltration with peripheral oxygen saturation lower than 93%. The median time from symptoms
onset to intervention initiation was..
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation.
FLCCC and
WCH
provide treatment protocols.
Submit